
Broadridge Financial Solutions, Inc. Electronic EDGAR Proof

Job Number:	BRHC10025189
Filer:	Nanobiotix S.A.
Form Type:	6-K
Reporting Period / Event Date:	05-26-2021
Customer Service Representative:	EDGARfilings@broadridge.com
Version Number:	1

This proof may not fit on letter-sized (8.5 x 11 inch) paper. If copy is cut off, please print to a larger format, e.g., legal-sized (8.5 x 14 inch) paper or oversized (11 x 17 inch) paper.

Accuracy of proof is guaranteed ONLY if printed to a PostScript printer using the correct PostScript driver for that printer make and model.

(this header is not part of the document)

EDGAR Submission Header Summary	
Submission Form Type	6-K
XBRL	NonXBRLSubmission
Period of Report	05-26-2021
Filer	Nanobiotix S.A.
CIK	0001760854
CCC	xxxxxxx
Exchanges	NONE
Co-Registrants	
Submission Contact	Broadridge Financial Solutions
Contact Phone Number	877-432-3342
Documents	5

Notification Emails	
Emails	aschen@jonesday.com
	pdevlin@jonesday.com
	EDGARfilings@broadridge.com

Documents	
6-K	brhc10025189_6k.htm
Description	6-K
EX-99.1	brhc10025189_ex99-1.htm
Description	Exhibit 99.1
GRAPHIC	image00003.jpg
GRAPHIC	image00004.jpg
GRAPHIC	image00005.jpg

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: May 26, 2021

Commission File Number: 001-39777

Nanobiotix S.A.

(Exact Name of Registrant as Specified in its Charter)

**60 Rue de Wattignies
75012 Paris, France**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

Exhibit Title

[99.1](#) Press Release, dated May 26, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANOBIOTIX S.A.
(Registrant)

May 26, 2021

By: /s/ Philippe Mauberna
Philippe Mauberna
Chief Financial Officer



PRESS RELEASE

NANOBIOTIX TO PARTICIPATE IN FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE

Paris, France; Cambridge, Massachusetts (USA); May 26, 2021 - NANOBIOTIX (Euronext : NANO — NASDAQ: NBTX – the “**Company**”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chief executive officer, will discuss the Company’s latest corporate and clinical developments in a fireside chat at the Jefferies Virtual Healthcare Conference on the 4th of June at 8:00 AM Eastern Time (14:00 Central European Time).

A live webcast of the discussion, as well as an archived recording may be accessed by visiting the [events section](#) of the Company’s website.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France, and has subsidiaries in Cambridge, Massachusetts (United States) as well as France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City in December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The Company’s resources are primarily devoted to the development of its lead product candidate—NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on [LinkedIn](#) and [Twitter](#)

Contacts

Nanobiotix

Communications Department

Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com

Investor Relations Department

Kate McNeil
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com

Media Relations

France – **Ulysse Communication**
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysses-communication.com

US – **Porter Novelli**
Stefanie Tuck
+1 (917) 390-1394
Stefanie.tuck@porternovelli.com

